Aspen Pharmacare Holdings Limited (APN.JO) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-06-30. APN.JO files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 47.79% | 30.00% | Fail |
| Interest-bearing investments | 8.36% | 30.00% | Pass |
| Non-permissible income | 0.83% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 26.95% | 33.00% | Pass |
| Interest-bearing investments | 4.72% | 33.00% | Pass |
| Non-liquid assets | 87.45% | at least 20.00% | Pass |
| Non-permissible income | 0.83% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 26.95% | 33.33% | Pass |
| Cash + interest-bearing securities | 4.72% | 33.33% | Pass |
| Accounts receivable | 12.55% | 33.33% | Pass |
| Non-permissible income | 0.83% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 26.95% | 33.33% | Pass |
| Cash + interest-bearing securities | 4.72% | 33.33% | Pass |
| Accounts receivable | 12.55% | 50.00% | Pass |
| Non-permissible income | 0.83% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 54.25% | 33.00% | Fail |
| Cash + interest-bearing securities | 9.49% | 33.00% | Pass |
| Accounts receivable | 15.77% | 33.00% | Pass |
| Non-permissible income | 0.83% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 46.84% | 33.00% | Fail |
| Cash + interest-bearing securities | 8.20% | 49.00% | Pass |
| Accounts receivable | 13.62% | 49.00% | Pass |
| Non-permissible income | 0.83% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 46.84% | 33.33% | Fail |
| Cash + interest-bearing securities | 8.20% | 33.33% | Pass |
| Accounts receivable | 21.82% | 49.00% | Pass |
| Non-permissible income | 0.83% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 57.80 | NEUTRAL |
| Stochastic %K (14) | 87.11 | SELL |
| CCI (20) | 93.00 | NEUTRAL |
| Williams %R (14) | -12.89 | SELL |
| MACD (12,26,9) | 58.65 | BUY |
| ROC (10) | 2.26 | BUY |
| Momentum (10) | 349.00 | BUY |
| EMA (10) | 15391.50 | BUY |
| SMA (10) | 15517.70 | BUY |
| EMA (20) | 15210.83 | BUY |
| SMA (20) | 15023.15 | BUY |
| EMA (30) | 15113.92 | BUY |
| SMA (30) | 14963.10 | BUY |
| EMA (50) | 14972.96 | BUY |
| SMA (50) | 15025.92 | BUY |
| EMA (100) | 14494.17 | BUY |
| SMA (100) | 14672.46 | BUY |
| EMA (200) | 13132.08 | BUY |
| SMA (200) | 13191.71 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Aspen Pharmacare Holdings Limited, together with its subsidiaries, operates as a specialty and branded pharmaceutical company in Africa, the Middle East, Europe, CIS, Australasia, Asia, and the Americas. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers sterile products in injectable form primarily administered in hospitals and prescribed and administered by physicians or in a retail pharmacy environment for therapeutic areas, such as anesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Sandostatin, Sustanon, and Xylocaine brands. It also provides over-the-counter topical products through retail pharmacy and fast-moving consumer goods sectors under the EMLA, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for therapeutic areas, including anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Meticorten brands. In addition, the company manufactures active pharmaceutical ingredients; finished dose form products manufactured for third parties; and heparin-based API to third parties. Further, it exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
